Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
AssigneeHoffmann-La Roche Inc.
InventorsLue Dai, Lu Gao
Life of this patent
Estimating the term…
Abstract
The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of a TLR7 agonist and an HBV capsid assembly inhibitor for use in the treatment of chronic hepatitis B patient.
Claims38
A pharmaceutical composition comprising a TLR7 agonist and an HBV capsid assembly inhibitor, in a pharmaceutically acceptable carrier.
A method for manufacturing a medicament for treatment or prophylaxis of hepatitis B virus infection, characterized in that a TLR7 agonist and an HBV capsid assembly inhibitor are used in the medicament.
A kit comprising a container comprising a TLR7 agonist and an HBV capsid assembly inhibitor.
A method for the treatment or prophylaxis of hepatitis B virus infection, comprising administration to a subject with an effective first amount of a TLR7 agonist, or pharmaceutically acceptable salt, enantiomer or diastereomer thereof;
- and a second amount of HBV capsid assembly inhibitor, or pharmaceutically acceptable salt, enantiomer or diastereomer thereof;
- or vice versa.
The invention as hereinbefore described.
Dependencies are inferred from the claim text.